

Safety and immunogenicity of an anti-Middle East respiratory syndrome vaccine: a phase 1, open-label, single-arm, dose-escalation study

Lancet Infectious Diseases, The
19, 1013-1022

DOI: [10.1016/s1473-3099\(19\)30266-x](https://doi.org/10.1016/s1473-3099(19)30266-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	First clinical trial of a MERS coronavirus DNA vaccine. Lancet Infectious Diseases, The, 2019, 19, 924-925.	4.6	13
2	Vaccine against Middle East respiratory syndrome coronavirus. Lancet Infectious Diseases, The, 2019, 19, 1054-1055.	4.6	11
3	Vaccine against Middle East respiratory syndrome coronavirus. Lancet Infectious Diseases, The, 2019, 19, 1053-1054.	4.6	4
4	Preventing drug-resistant tuberculosis transmission. Lancet Infectious Diseases, The, 2020, 20, 157-158.	4.6	5
5	Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial. Frontiers in Immunology, 2020, 11, 561851.	2.2	4
6	Prospects for a safe COVID-19 vaccine. Science Translational Medicine, 2020, 12, .	5.8	204
7	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine, 2020, 383, 2427-2438.	13.9	1,242
8	Engineering Antiviral Vaccines. ACS Nano, 2020, 14, 12370-12389.	7.3	50
9	A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 2020, 5, 237.	7.1	427
10	New insights on possible vaccine development against SARS-CoV-2. Life Sciences, 2020, 260, 118421.	2.0	8
11	Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infectious Diseases of Poverty, 2020, 9, 99.	1.5	59
12	Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity, 2020, 53, 248-263.	6.6	281
13	Regulatory Considerations on the Development of mRNA Vaccines. Current Topics in Microbiology and Immunology, 2020, , 187-205.	0.7	16
14	Current Status of COVID-19 (Pre)Clinical Vaccine Development. Angewandte Chemie, 2020, 132, 19045-19057.	1.6	4
15	Current Status of COVID-19 (Pre)Clinical Vaccine Development. Angewandte Chemie - International Edition, 2020, 59, 18885-18897.	7.2	61
16	Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. Frontiers in Medicine, 2020, 7, 581521.	1.2	42
17	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. Frontiers in Oncology, 2020, 10, 572329.	1.3	7
18	COVID-19: Mechanisms of Vaccination and Immunity. Vaccines, 2020, 8, 404.	2.1	81

#	ARTICLE	IF	CITATIONS
19	Transmission and evolutionary dynamics of human coronavirus OC43 strains in coastal Kenya investigated by partial spike sequence analysis, 2015-16. <i>Virus Evolution</i> , 2020, 6, veaa031.	2.2	4
20	Protection against <i>Borrelia burgdorferi</i> infection mediated by a synthetically engineered DNA vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2114-2122.	1.4	4
21	Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?. <i>Viruses</i> , 2020, 12, 861.	1.5	43
22	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. <i>Frontiers in Immunology</i> , 2020, 11, 579250.	2.2	72
23	The Current Status of COVID-19 Vaccines. <i>Frontiers in Genome Editing</i> , 2020, 2, 579297.	2.7	25
24	COVID-19 in health-care workers: lessons from SARS and MERS epidemics and perspectives for chemoprophylaxis and vaccines.. <i>Expert Review of Vaccines</i> , 2020, 19, 937-947.	2.0	12
25	Biomedical Science to Tackle the COVID-19 Pandemic: Current Status and Future Perspectives. <i>Molecules</i> , 2020, 25, 4620.	1.7	23
26	Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2366-2369.	1.4	7
27	Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects. <i>Vaccines</i> , 2020, 8, 534.	2.1	44
28	An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies. <i>Expert Review of Vaccines</i> , 2020, 19, 817-829.	2.0	10
29	Vaccines targeting SARS-CoV-2 tested in humans. <i>Nature Medicine</i> , 2020, 26, 1336-1338.	15.2	7
30	Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. <i>Frontiers in Medical Technology</i> , 2020, 2, 571030.	1.3	29
31	Vaccines for COVID-19. <i>Clinical and Experimental Immunology</i> , 2020, 202, 162-192.	1.1	185
32	DNA-Encoded Glutamine Synthetase Enzyme as Ammonia-Lowering Therapeutic for Hyperammonemia. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 379-391.	2.0	2
33	<p>Middle East Respiratory Syndrome – What Every Otolaryngologist Should Know: A Review</p>. <i>International Journal of General Medicine</i> , 2020, Volume 13, 483-489.	0.8	1
34	Coronavirus vaccine development: from SARS and MERS to COVID-19. <i>Journal of Biomedical Science</i> , 2020, 27, 104.	2.6	287
35	Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9411.	1.2	85
36	COVID-19: Coronavirus Vaccine Development Updates. <i>Frontiers in Immunology</i> , 2020, 11, 602256.	2.2	143

#	ARTICLE	IF	CITATIONS
37	The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 19, 1-12.	2.0	10
38	Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population. <i>Seminars in Immunopathology</i> , 2020, 42, 619-634.	2.8	41
39	COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. <i>Vaccines</i> , 2020, 8, 649.	2.1	42
40	Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. <i>Journal of Infectious Diseases</i> , 2020, 222, 180-182.	1.9	12
41	Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome. <i>Emerging Infectious Diseases</i> , 2020, 26, 1102-1112.	2.0	6
42	Immunogenicity of a DNA vaccine candidate for COVID-19. <i>Nature Communications</i> , 2020, 11, 2601.	5.8	514
43	Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. <i>Biomedical Journal</i> , 2020, 43, 341-354.	1.4	81
44	COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. <i>Therapeutic Delivery</i> , 2020, 11, 245-268.	1.2	113
45	The Challenges of Vaccine Development against a New Virus during a Pandemic. <i>Cell Host and Microbe</i> , 2020, 27, 699-703.	5.1	88
46	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	6.6	1,387
47	Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1175-1191.	5.7	16
48	Overview of lethal human coronaviruses. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 89.	7.1	218
49	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2. <i>Vaccines</i> , 2020, 8, 293.	2.1	12
50	Emergence of novel coronavirus and progress toward treatment and vaccine. <i>Reviews in Medical Virology</i> , 2020, 30, e2116.	3.9	8
51	Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). <i>Journal of Biomedical Science</i> , 2020, 27, 72.	2.6	36
52	Vaccines against Coronaviruses: The State of the Art. <i>Vaccines</i> , 2020, 8, 309.	2.1	49
53	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. <i>International Immunopharmacology</i> , 2020, 86, 106717.	1.7	77
54	Vaccines for COVID-19: The current state of play. <i>Paediatric Respiratory Reviews</i> , 2020, 35, 43-49.	1.2	170

#	ARTICLE	IF	CITATIONS
55	Application of a Risk Analysis Tool to Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Outbreak in Saudi Arabia. <i>Risk Analysis</i> , 2020, 40, 915-925.	1.5	8
56	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. <i>ACS Central Science</i> , 2020, 6, 315-331.	5.3	1,015
57	The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses. <i>Frontiers in Microbiology</i> , 2020, 11, 658.	1.5	86
58	In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies. <i>BioDrugs</i> , 2020, 34, 273-293.	2.2	41
59	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 623.	1.0	381
60	COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. <i>Journal of Virology</i> , 2020, 94, .	1.5	79
61	COVID-19: Progress in diagnostics, therapy and vaccination. <i>Theranostics</i> , 2020, 10, 7821-7835.	4.6	121
62	In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. <i>Advanced Science</i> , 2020, 7, 1902802.	5.6	30
63	Coronaviruses in animals and humans. <i>BMJ</i> , The, 2020, 368, m634.	3.0	23
64	Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model. <i>Vaccines</i> , 2020, 8, 21.	2.1	3
65	Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. <i>Microbes and Infection</i> , 2020, 22, 74-79.	1.0	288
66	COVID-19: Therapeutics and Their Toxicities. <i>Journal of Medical Toxicology</i> , 2020, 16, 284-294.	0.8	82
67	DNA vaccines: prime time is now. <i>Current Opinion in Immunology</i> , 2020, 65, 21-27.	2.4	123
68	Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection. <i>MBio</i> , 2020, 11, .	1.8	43
69	Novel Coronavirus: Current Understanding of Clinical Features, Diagnosis, Pathogenesis, and Treatment Options. <i>Pathogens</i> , 2020, 9, 297.	1.2	44
70	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 816-826.	4.6	182
71	Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 827-838.	4.6	125
72	Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 760-761.	4.6	4

#	ARTICLE	IF	CITATIONS
73	Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains. <i>Infectious Diseases and Therapy</i> , 2020, 9, 255-274.	1.8	142
74	Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial. <i>Drug Metabolism Reviews</i> , 2021, 53, 141-170.	1.5	39
75	Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. <i>Genomics</i> , 2021, 113, 1221-1232.	1.3	126
76	The increasing importance of the novel Coronavirus. <i>Hospital Practice (1995)</i> , 2021, 49, 1-11.	0.5	8
77	The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies. <i>International Immunopharmacology</i> , 2021, 92, 107051.	1.7	33
78	SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies. <i>Asian Journal of Pharmaceutical Sciences</i> , 2021, 16, 136-146.	4.3	24
79	Actin networks regulate the cell membrane permeability during electroporation. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2021, 1863, 183468.	1.4	36
80	Learning from the past: development of safe and effective COVID-19 vaccines. <i>Nature Reviews Microbiology</i> , 2021, 19, 211-219.	13.6	126
81	Current advances in the development of SARS-CoV-2 vaccines. <i>International Journal of Biological Sciences</i> , 2021, 17, 8-19.	2.6	114
82	A review of COVID-19 vaccines and major considerations for diabetic patients. <i>Biotechnology and Applied Biochemistry</i> , 2022, 69, 30-40.	1.4	6
83	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 168-189.	6.6	62
84	DNA vaccines against COVID-19: Perspectives and challenges. <i>Life Sciences</i> , 2021, 267, 118919.	2.0	172
85	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. <i>EClinicalMedicine</i> , 2021, 31, 100689.	3.2	206
86	Non-viral COVID-19 vaccine delivery systems. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 137-151.	6.6	152
87	SARS-CoV-2 vaccine candidates in rapid development. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 644-653.	1.4	30
88	Strategies for Vaccination: Conventional Vaccine Approaches Versus New-Generation Strategies in Combination with Adjuvants. <i>Pharmaceutics</i> , 2021, 13, 140.	2.0	28
90	Innovative Strategies to Understand and Control COVID-19 Disease. <i>Algorithms for Intelligent Systems</i> , 2021, , 209-230.	0.5	0
91	Unsupervised Learning Model to Uncover. <i>Lecture Notes in Computer Science</i> , 2021, , 544-559.	1.0	0

#	ARTICLE	IF	CITATIONS
92	Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185.		1
93	COVID-19 vaccine: where are we now and where should we go?. Expert Review of Vaccines, 2021, 20, 23-44.	2.0	107
94	The COVID-19 Vaccine Landscape. Advances in Experimental Medicine and Biology, 2021, 1318, 549-573.	0.8	9
95	Coronavirus (SARS-CoV-2): a systematic review for potential vaccines. Human Vaccines and Immunotherapeutics, 2022, 18, 1-18.	1.4	11
96	Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity. Journal of Virology, 2021, 95, .	1.5	48
97	Walter Reed Army Institute of Research (WRAIR): Fifty Years of Achievements That Impact Science and Society. Military Medicine, 2021, 186, 72-77.	0.4	4
98	Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens. Genes and Cancer, 2021, 12, 51-64.	0.6	6
99	Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates. Vaccines, 2021, 9, 307.	2.1	28
100	Frontrunners in the race to develop a SARS-CoV-2 vaccine. Canadian Journal of Microbiology, 2021, 67, 189-212.	0.8	11
101	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2021, 170, 113-141.	6.6	71
102	COVID-19: Insights into Potential Vaccines. Microorganisms, 2021, 9, 605.	1.6	31
103	Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. Pharmaceutics, 2021, 13, 501.	2.0	15
104	NIH funding for vaccine readiness before the COVID-19 pandemic. Vaccine, 2021, 39, 2458-2466.	1.7	26
105	Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines. Drug Development and Industrial Pharmacy, 2021, 47, 673-684.	0.9	3
106	Exploring status of emergency drugs and vaccine development in Covid-19 pandemic: an update. VirusDisease, 2021, 32, 198-210.	1.0	6
107	The UK approach to COVID-19 vaccination: why was it so different?. Drugs in Context, 2021, 10, 1-9.	1.0	3
108	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews, 2021, 172, 314-338.	6.6	75
110	Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus. JCI Insight, 2021, 6, .	2.3	7

#	ARTICLE	IF	CITATIONS
111	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 74.	2.9	198
113	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. <i>Vaccines</i> , 2021, 9, 588.	2.1	12
114	Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. <i>Vaccine</i> , 2021, 39, 4108-4116.	1.7	85
116	Vaccine development lessons between HIV and COVID-19. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 759-761.	4.6	3
117	A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. <i>IScience</i> , 2021, 24, 102699.	1.9	15
118	Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2021, 356, 577599.	1.1	62
119	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
120	Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections. <i>Pathogens</i> , 2021, 10, 1051.	1.2	18
121	Amplicon and Metagenomic Analysis of Middle East Respiratory Syndrome (MERS) Coronavirus and the Microbiome in Patients with Severe MERS. <i>MSphere</i> , 2021, 6, e0021921.	1.3	12
123	Meta-analysis and comprehensive study of coronavirus outbreaks: SARS, MERS and COVID-19. <i>Journal of Infection and Public Health</i> , 2021, 14, 1051-1064.	1.9	13
124	Herramientas biotecnológicas en el diagnóstico, prevención y tratamiento frente a pandemias. <i>Revista Bionatura</i> , 2021, 3, 2091-2113.	0.1	0
125	Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/III clinical study by intradermal route in healthy subjects in India. <i>EClinicalMedicine</i> , 2021, 38, 101020.	3.2	121
126	COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. <i>Molecular Therapy</i> , 2022, 30, 311-326.	3.7	54
128	Covid-19 Vaccination "A Saviour from Pandemic". <i>Journal of Evolution of Medical and Dental Sciences</i> , 2021, 10, 3424-3429.	0.1	1
129	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <i>Cell Host and Microbe</i> , 2021, 29, 1437-1453.e8.	5.1	53
130	Lethal Human Coronavirus Infections and the Role of Vaccines in Their Prevention. , 2021, , 533-549.		1
132	Coronaviruses: An Updated Overview of Their Replication and Pathogenesis. <i>Methods in Molecular Biology</i> , 2020, 2203, 1-29.	0.4	132
134	A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008788.	1.3	11

#	ARTICLE	IF	CITATIONS
136	Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. <i>Journal of Microbiology and Biotechnology</i> , 2020, 30, 1109-1115.	0.9	12
137	In Silico Modeling as a Perspective in Developing Potential Vaccine Candidates and Therapeutics for COVID-19. <i>Coatings</i> , 2021, 11, 1273.	1.2	19
138	Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena. <i>Biologics</i> , 2021, 1, 337-356.	2.3	58
139	Recent Update of COVID-19 Vaccines. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	0
140	Editorial: DNA Vaccines. <i>Frontiers in Medical Technology</i> , 2021, 3, 782986.	1.3	0
141	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2020, 6, 41-80.	0.1	0
142	Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2111075118.	3.3	9
143	Revisiting the role of pulsed electric fields in overcoming the barriers to in vivo gene electrotransfer. <i>Bioelectrochemistry</i> , 2022, 144, 107994.	2.4	20
144	Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. <i>Lancet Microbe</i> , The, 2022, 3, e11-e20.	3.4	25
146	Novel suction-based in vivo cutaneous DNA transfection platform. <i>Science Advances</i> , 2021, 7, eabj0611.	4.7	17
148	Current Scenario of Covid-19 with Epidemiological and Phylogenetic Analysis of Pakistani Coronavirus: A Review. <i>Journal of Bioresource Management</i> , 2020, 7, 45-65.	0.4	0
152	Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. <i>Archives of Academic Emergency Medicine</i> , 2020, 8, e41.	0.2	82
153	Viral-vectored vaccines Against SARS-CoV-2. , 2022, , 115-127.		1
154	Prevention of Emerging Infections in Children. <i>Pediatric Clinics of North America</i> , 2022, 69, 185-202.	0.9	2
155	Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity. <i>Frontiers in Oncology</i> , 2021, 11, 778989.	1.3	18
156	Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020â€“2026: A modeling study. <i>Infectious Disease Modelling</i> , 2022, 7, 62-81.	1.2	14
157	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0012321.	5.7	10
158	Advances in mRNA and other vaccines against MERS-CoV. <i>Translational Research</i> , 2022, 242, 20-37.	2.2	11

#	ARTICLE	IF	CITATIONS
159	A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity. <i>Vaccine</i> , 2021, 39, 7175-7181.	1.7	3
160	Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences. <i>Molecular Therapy</i> , 2022, 30, 2058-2077.	3.7	10
161	Adenovirus-based vaccines as a platform for pandemic preparedness against emerging viral pathogens. <i>Molecular Therapy</i> , 2022, 30, 1822-1849.	3.7	24
162	Immunological challenges of the new infections: corona viruses. , 2022, , 395-450.		2
163	Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	2
164	A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. <i>Science Advances</i> , 2022, 8, eabh3827.	4.7	27
165	Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies. <i>Journal of Microbiology</i> , 2022, 60, 238-246.	1.3	5
166	Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa. <i>Nanomaterials</i> , 2022, 12, 226.	1.9	20
167	Advanced Materials for SARS-CoV-2 Vaccines. <i>Advanced Materials</i> , 2022, 34, e2107781.	11.1	25
168	Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer. <i>Nature Communications</i> , 2022, 13, 695.	5.8	2
170	Immunogenic Epitope-Based Vaccine Prediction from Surface Glycoprotein of MERS-CoV by Deploying Immunoinformatics Approach. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 77.	0.9	5
171	DNA vaccines join the fight against COVID-19. <i>Lancet, The</i> , 2022, 399, 1281-1282.	6.3	17
172	Vaccine-induced immune responses against SARS-CoV-2 infections. <i>Exploration of Immunology</i> , 0, , 356-373.	1.7	0
173	Middle East Respiratory Syndrome Coronavirus. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 828-838.	0.8	7
174	Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. <i>Methods in Molecular Biology</i> , 2022, 2410, 229-263.	0.4	1
175	Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. <i>Npj Vaccines</i> , 2022, 7, 49.	2.9	7
176	Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vaccine Following Intradermal Immunization With Suction Delivery. <i>Frontiers in Virology</i> , 0, 2, .	0.7	9
178	Immune Response to SARS-CoV-2 Vaccines. <i>Biomedicines</i> , 2022, 10, 1464.	1.4	24

#	ARTICLE	IF	CITATIONS
179	Vaccine Preventable Zoonotic Diseases: Challenges and Opportunities for Public Health Progress. <i>Vaccines</i> , 2022, 10, 993.	2.1	10
180	Coronaviruses. , 2023, , 277-306.		0
181	Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100685.	3.3	11
182	Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. <i>Nature Communications</i> , 2022, 13, .	5.8	6
183	Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels. <i>Vaccines</i> , 2022, 10, 1330.	2.1	6
185	Nature of viruses and pandemics: Coronaviruses. <i>Current Research in Immunology</i> , 2022, 3, 151-158.	1.2	3
186	A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. <i>DARU, Journal of Pharmaceutical Sciences</i> , 0, , .	0.9	5
188	Optimization of In Vivo Electroporation Conditions and Delivery of DNA Vaccine Encoding SARS-CoV-2 RBD Using the Determined Protocol. <i>Pharmaceutics</i> , 2022, 14, 2259.	2.0	7
189	Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses. <i>Vaccines</i> , 2022, 10, 1805.	2.1	3
190	Postoperative Management During the Pandemic Coronavirus Disease 2019 (COVID-19) Era. <i>European Journal of Medical and Health Sciences</i> , 2022, 4, 26-29.	0.1	0
191	A β 42PD1 fusion-expressing DNA vaccine elicits enhanced adaptive immune response to HIV-1: the key role of TLR4. <i>Virology Journal</i> , 2022, 19, .	1.4	1
192	Evaluation of Zika virus DNA vaccines based on NS1 and domain III of E. <i>International Immunopharmacology</i> , 2022, 113, 109308.	1.7	1
193	Elicitation of immune responses against Nipah virus by an engineered synthetic DNA vaccine. <i>Frontiers in Virology</i> , 0, 2, .	0.7	0
194	Delivery of a DNA vaccine encoding SARS-CoV-2 receptor-binding domain (RBD) by electroporation. <i>Meditsinskii Akademicheskii Zhurnal</i> , 2022, 2, 191-196.	0.2	0
195	Respiratory mucosal vaccination of peptide-polyamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge. <i>Biomaterials</i> , 2023, 292, 121907.	5.7	11
196	Large-Scale Production and Business Plan for Novel Corona Vaccine. <i>Microorganisms for Sustainability</i> , 2022, , 303-323.	0.4	0
197	Oral Delivery of SARS-CoV-2 DNA Vaccines Using Attenuated <i>Salmonella typhimurium</i> as a Carrier in Rat. <i>Molecular Genetics, Microbiology and Virology</i> , 2022, 37, 159-166.	0.0	5
198	Vaccine development for zoonotic viral diseases caused by positive-sense single-stranded RNA viruses belonging to the <i>Coronaviridae</i> and <i>Togaviridae</i> families (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 25, .	0.8	2

#	ARTICLE	IF	CITATIONS
199	The need and challenges for development of vaccines against emerging infectious diseases. <i>Jornal De Pediatria</i> , 2023, 99, S37-S45.	0.9	4
200	A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines. <i>Npj Vaccines</i> , 2022, 7, .	2.9	2
201	A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19. <i>Molecular Therapy</i> , 2023, 31, 788-800.	3.7	8
203	Improved DNA Vaccine Delivery with Needle-Free Injection Systems. <i>Vaccines</i> , 2023, 11, 280.	2.1	21
204	Computational approaches in COVID-19 vaccine development. , 2023, , 339-350.		0
205	Preclinical safety assessment of the suction-assisted intradermal injection of the SARS-CoV-2 DNA vaccine candidate pGO-1002 in white rabbit. <i>Archives of Toxicology</i> , 2023, 97, 1177-1189.	1.9	1
206	Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase. <i>Nature Communications</i> , 2023, 14, .	5.8	4
207	Vaccination strategies for mitigation of MERS-CoV outbreaks. <i>The Lancet Global Health</i> , 2023, 11, e644-e645.	2.9	1
208	Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines. <i>International Immunopharmacology</i> , 2023, 118, 109998.	1.7	1
209	A Thermal-Stable Protein Nanoparticle That Stimulates Long Lasting Humoral Immune Response. <i>Vaccines</i> , 2023, 11, 426.	2.1	4
210	Gene-encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunity. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 0, , .	3.3	1
211	The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review. <i>J</i> , 2023, 6, 220-235.	0.6	3
217	Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.		0
218	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
229	Approaches to Improve the Immunogenicity of Plasmid DNA-Based Vaccines against COVID-19. , 0, , .		0